Teleflex (NYSE:TFX) Cut to "Hold" at Zacks Research

Key Points

• Teleflex has been downgraded from a "strong-buy" to a "hold" rating by Zacks Research and is currently rated "hold" by the consensus of analysts.
• Mizuho has raised Teleflex's target price to $135.00, while Wells Fargo lowered it to $131.00, illustrating mixed outlooks among analysts.
• Insider transactions have recently increased, with significant purchases made by a director and the CEO, indicating a potential confidence from the management in the company's future performance.

Teleflex (NYSE:TFX - Get Free Report) was downgraded by analysts at Zacks Research from a "strong-buy" rating to a "hold" rating in a research note issued on Tuesday,Zacks.com reports.

A number of other research analysts have also recently commented on TFX. Mizuho raised their target price on Teleflex from $130.00 to $135.00 and gave the company a "neutral" rating in a research note on Friday, August 1st. Wall Street Zen cut Teleflex from a "strong-buy" rating to a "buy" rating in a research note on Monday, September 15th. Wells Fargo & Company lowered their price objective on Teleflex from $137.00 to $131.00 and set an "equal weight" rating for the company in a research note on Friday, August 1st. Finally, Royal Bank Of Canada lifted their price objective on Teleflex from $130.00 to $135.00 and gave the company a "sector perform" rating in a research note on Friday, August 1st. One investment analyst has rated the stock with a Buy rating, nine have assigned a Hold rating and one has given a Sell rating to the company's stock. According to MarketBeat, the company currently has a consensus rating of "Hold" and an average target price of $141.57.

Teleflex Stock Performance

Shares of TFX traded up $0.72 during mid-day trading on Tuesday, hitting $124.64. The stock had a trading volume of 21,240 shares, compared to its average volume of 764,414. The firm has a market cap of $5.51 billion, a P/E ratio of 29.53, a PEG ratio of 1.71 and a beta of 1.05. The business has a fifty day moving average price of $122.91 and a 200-day moving average price of $124.96. The company has a debt-to-equity ratio of 0.42, a current ratio of 2.41 and a quick ratio of 1.44. Teleflex has a 52 week low of $108.90 and a 52 week high of $243.90.

Teleflex (NYSE:TFX - Get Free Report) last announced its earnings results on Thursday, July 31st. The medical technology company reported $3.73 earnings per share for the quarter, topping analysts' consensus estimates of $3.36 by $0.37. The business had revenue of $780.90 million for the quarter, compared to analyst estimates of $771.53 million. Teleflex had a return on equity of 15.08% and a net margin of 6.31%.The company's quarterly revenue was up 4.2% compared to the same quarter last year. During the same period in the prior year, the company earned $3.42 EPS. Teleflex has set its FY 2025 guidance at 13.900-14.300 EPS. On average, equities research analysts expect that Teleflex will post 13.98 EPS for the current year.

Insider Buying and Selling

In related news, Director Stuart A. Randle purchased 1,000 shares of the business's stock in a transaction on Tuesday, August 5th. The stock was acquired at an average price of $115.86 per share, with a total value of $115,860.00. Following the completion of the acquisition, the director owned 7,547 shares of the company's stock, valued at approximately $874,395.42. This trade represents a 15.27% increase in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, CEO Liam Kelly purchased 1,500 shares of the business's stock in a transaction on Tuesday, August 5th. The shares were bought at an average cost of $115.07 per share, with a total value of $172,605.00. Following the acquisition, the chief executive officer directly owned 45,267 shares of the company's stock, valued at $5,208,873.69. This trade represents a 3.43% increase in their position. The disclosure for this purchase can be found here. Insiders have purchased a total of 5,500 shares of company stock valued at $633,590 over the last ninety days. 1.40% of the stock is owned by insiders.

Institutional Investors Weigh In On Teleflex

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Osaic Holdings Inc. increased its holdings in Teleflex by 17.5% during the 2nd quarter. Osaic Holdings Inc. now owns 1,247 shares of the medical technology company's stock worth $148,000 after purchasing an additional 186 shares during the period. State of Wyoming acquired a new position in shares of Teleflex in the 2nd quarter valued at about $111,000. Westwood Holdings Group Inc. lifted its holdings in shares of Teleflex by 10.2% in the 2nd quarter. Westwood Holdings Group Inc. now owns 121,534 shares of the medical technology company's stock valued at $14,385,000 after buying an additional 11,261 shares during the period. Public Sector Pension Investment Board raised its holdings in Teleflex by 2.3% in the 2nd quarter. Public Sector Pension Investment Board now owns 150,669 shares of the medical technology company's stock worth $17,833,000 after purchasing an additional 3,371 shares during the period. Finally, Headlands Technologies LLC purchased a new stake in Teleflex during the 2nd quarter worth approximately $538,000. 95.62% of the stock is currently owned by hedge funds and other institutional investors.

Teleflex Company Profile

Teleflex Incorporated designs, develops, manufactures, and supplies single-use medical devices for common diagnostic and therapeutic procedures in critical care and surgical applications worldwide. The company provides vascular access products that comprise Arrow branded catheters, catheter navigation and tip positioning systems, and intraosseous access systems for the administration of intravenous therapies, the measurement of blood pressure, and the withdrawal of blood samples through a single puncture site.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.